Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.39 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4912676 | 1.00 | ANPEP (0.44) | ANPEPFOLH1CPB2GSRERAP2 | |
| Hydrochloric Acid SCHEMBL7202066 | 0.98 | ANPEP (0.43) | ANPEPFOLH1CPB2GSRERAP2 | |
| SCHEMBL27593963 | 0.94 | ANPEP (0.39) | ANPEPFOLH1CPB2GSRERAP2 | |
| SCHEMBL12890801 | 0.94 | ANPEP (0.39) | ANPEPFOLH1CPB2GSRERAP2 | |
| SCHEMBL16263606 | 0.88 | ERAP2 (0.43) | ANPEPFOLH1ERAP2LNPEPSIRT6 | |
| SCHEMBL18720312 | 0.85 | CPB2 (0.39) | ANPEPFOLH1CPB2GSRSIRT6 | |
| SCHEMBL7224727 | 0.85 | ANPEP (0.44) | ANPEPFOLH1CPB2GSRERAP2 | |
| SCHEMBL7224725 | 0.85 | ANPEP (0.44) | ANPEPFOLH1CPB2GSRERAP2 | |
| SCHEMBL7576584 | 0.85 | ANPEP (0.44) | ANPEPFOLH1CPB2GSRERAP2 | |
| SCHEMBL12013082 | 0.83 | ANPEP (0.46) | ANPEPFOLH1CPB2GSRERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786642-B2 | In situ forming hemostatic form implants | ARSENAL MEDICAL, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786642-B2 | In situ forming hemostatic form implants | ARSENAL MEDICAL, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230263900-A1 | DENDRIMER-DRUG CONJUGATE | STARPHARMA PTY LTD (AU) | 2023-08-24 | — | — | US | disclosed |
| US-20230241360-A1 | TEMPORARY OCCLUSION BALLOON DEVICES AND METHODS FOR PREVENTING BLOOD FLOW THROUGH A VASCULAR PERFORATION | SPECTRANETICS LLC (CO) | 2023-08-03 | — | — | US | disclosed |
| US-20230241360-A1 | TEMPORARY OCCLUSION BALLOON DEVICES AND METHODS FOR PREVENTING BLOOD FLOW THROUGH A VASCULAR PERFORATION | SPECTRANETICS LLC (CO) | 2023-08-03 | — | — | US | disclosed |
| US-20220105248-A1 | IN SITU FORMING HEMOSTATIC FOAM IMPLANTS | ARSENAL MEDICAL, INC. | 2022-04-07 | — | — | US | disclosed |
| US-11246964-B2 | In situ forming hemostatic foam implants | ARSENAL MEDICAL, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-10980920-B2 | In situ forming hemostatic foam implants | ARSENAL MEDICAL, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200405921-A1 | IN SITU FORMING HEMOSTATIC FORM IMPLANTS | ARSENAL MEDICAL, INC. | 2020-12-31 | — | — | US | disclosed |
| EP-2673293-B1 | SURROGATES OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF | HARVARD COLLEGE (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20120265287-A1 | In-Situ Forming Foams for Treatment of Aneurysms | ARSENAL MEDICAL, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120265287-A1 | In-Situ Forming Foams for Treatment of Aneurysms | ARSENAL MEDICAL, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120107439-A1 | IN SITU FORMING HEMOSTATIC FOAM IMPLANTS | ARSENAL MEDICAL, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120107439-A1 | IN SITU FORMING HEMOSTATIC FOAM IMPLANTS | ARSENAL MEDICAL, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20110294995-A1 | Functionalized nanoparticles and other particles and methods for making and using same | NORTH DAKOTA STATE UNIVERSITY | 2011-12-01 | — | — | US | disclosed |
| US-20110202016-A1 | SYSTEMS AND METHODS RELATING TO POLYMER FOAMS | ARSENAL MEDICAL, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110202016-A1 | SYSTEMS AND METHODS RELATING TO POLYMER FOAMS | ARSENAL MEDICAL, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20100226967-A1 | IMAGING AND THERAPEUTIC METHOD USING PROGENITOR CELLS | PURDUE RESEARCH FOUNDATION (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100055735-A1 | EX VIVO FLOW CYTOMETRY METHOD AND DEVICE | LOW PHILIP STEWART | 2010-03-04 | — | — | US | disclosed |
| US-20070134335-A1 | POLYPEPTIDES WITH THE CAPACITY TO ENTRAP DRUGS AND RELEASE THEM IN A CONTROLLED WAY | FARMHISPANIA S.A. (ES) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070134335-A1 | POLYPEPTIDES WITH THE CAPACITY TO ENTRAP DRUGS AND RELEASE THEM IN A CONTROLLED WAY | DNPEP, LNPEP, PTMS | ANPEP 7/4885FOLH1 51/4885CPB2 497/4885 |
| US-20100226967-A1 | IMAGING AND THERAPEUTIC METHOD USING PROGENITOR CELLS | CD44, MYADM, ANTXR2 | ANPEP 947/4885FOLH1 316/4885CPB2 591/4885 |
| US-20110294995-A1 | Functionalized nanoparticles and other particles and methods for making and using same | NCL, RNGTT, CD63 | ANPEP 387/4885FOLH1 487/4885CPB2 3225/4885 |
| US-20230263900-A1 | DENDRIMER-DRUG CONJUGATE | SARS1, MMAB, PAM | ANPEP 105/4885FOLH1 27/4885CPB2 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.